Momenta Pharmaceuticals Inc (MNTA.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2018||President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director|
|51||2017||Chief Operating Officer, Chief Scientific Officer|
|60||2008||Senior Vice President, General Counsel, Secretary|
- BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63
- BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18
- BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa
- BRIEF-Momenta Pharmaceuticals Announces Positive Outcome For Contracted Glatopa
- BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However